Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 2021

View Archived Issues

Turning tsetse fly meal to poison for sleeping sickness control

Maytansinoid analogue conjugated to gold nanoparticles inhibits tumor growth in HCC mouse model

RSV vaccine candidate GSK-3844766A advances into phase IIb extension study

LINC01271 is a therapeutic target in breast cancer

CTSC-RAB38 fusion transcript increases risk of hemorrhage in brain arteriovenous malformations

Personal neoantigen vaccine generates broad and durable memory T-cell responses in melanoma patients

Ongoing BLAZE-4 trial expanded to evaluate bamlanivimab plus VIR-7831 in COVID-19

First patient dosed in phase II study of VB-201 in COVID-19

Termination of Kuwait study of Avigan in hospitalized patients with moderate to severe COVID-19

IMPACT Therapeutics presents ATM kinase inhibitors

Suzhou Kintor Pharmaceuticals patents c-MYC inhibitors

Nuvation Bio identifies new BET inhibitors

Chinese investigators describe new KRAS mutant inhibitors

Astrocytic ApoE mediates memory consolidation in mice

Merck KGaA patents TLR antagonists

Dosing initiates in phase I study of CORVax12, a unique DNA vaccine candidate against COVID-19

FDA gives clearance to initiate clinical development of KP-879

Vaxil provides development updates for its COVID-19 vaccine candidate

Zymeworks advances phase I trial of HER2-targeted ADC ZW-49

Phase III trial of tislelizumab in esophageal squamous cell carcinoma meets primary endpoint

Merck & Co. presents preliminary safety and PK data for islatravir in HIV-1 pre-exposure prophylaxis

Applied Genetic Technologies provides update on achromatopsia trials

BioInvent reports interim data from phase I/IIa trial of BI-1206 in NHL

Enrollment completed in phase I/IIa study of Aggrastat in aneurysmal subarachnoid hemorrhage

New in-home trial studies famotidine for outpatient treatment of COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...